PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy

Publication: ASCO 2026, Abstract #621 Authors: David Page Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Background: Neoadjuvant outcomes are variable in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), highlighting the unmet need for predictive biomarkers. Read More

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More

Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy

Publication: ASBrS 2026, Abstract Number: 1062 Authors:Nathalie Johnson, Mehran Habibi, Marcela Mazo, Ahmed Elkhanany, Fengting Yan, Nicole Sookhan, J. Jaime Alberty-Oller, Laila Samiian, Eric Brown, Linsey Gold, Alfredo Santillan, Eduardo Dias, Sasha Davis, Laura Lee, Constantine Godellas, Abigail Beard, Gordan Srkalovic, Beth-Ann Lesnikoski, Sahra Uygun, Christina Page, Nicole Stivers, Read More

Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer Outcomes

Publication: JCO Precis Oncol. 2026 Apr;10(4):e2500926. doi: 10.1200/PO-25-00926. Epub 2026 Apr 9. Authors: Reine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, Benjamin Hauk, Yilun Sun, Priyanka S Rana, Citlally Lopez-Flores, Breanna N McBean, Kassidy M Jungles, Trisha Lal, Nihit Mehta, Philip Bomeisl, Amanda L Amin, Alberto J Montero, Siran Koroukian, Read More

Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer

Publication: npj Breast Cancer 12, 68 (2026). https://doi.org/10.1038/s41523-026-00932-1Authors: Sonya Reid; Lindsay Venton; Jennifer G. Whisenant; Anne E. Weidner; Jennifer Wei; Harshini Ramaswamy; Christa Dreezen; Nicole Chmielewski-Stivers;Andrea R. Menicucci; William Audeh; Tuya PalTitle: Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2– breast cancerAbstract:We compared clinicopathologic features, MammaPrint and Read More

Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor–Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer

Publication: SABCS 2025 Authors: Saya Jacob, Cynthia Wu, Annuska Glas, Christina Yau, Lamorna Brown-Swigart, Gillian Hirst, Tufia Haddad, Karthik Giridhar, Anthony Elias, Rita Mukhtar, Laura Huppert, Kathy Albain, Doug Yee, Laura van’t Veer, Laura Esserman2, Jo Chien Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients Read More